Phase I Study of Fruquintinib(HMPL-013) in Patients With Advanced Solid Tumors

NCT01645215 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

40

Enrollment

INDUSTRY

Sponsor class

Conditions

Tumor

Interventions

DRUG: Fruquintinib

Sponsor

Hutchison Medipharma Limited

Collaborators

[object Object]